< Back to topics
> Cover Page, Authors, Institutions
> Purpose/Objective
> Materials/Methods
> Results/Discussion
> Conclusions
> View tables/images/videos
> View abstract & virtual poster in original format
|
|
Results:
The median PSA was 7.1 ng/ml (range 1‐189) and the median follow‐up was 7.1 years (range 1‐16). 48/584 (8.2%) had a persistent positive PB. Of the 21 with a positive SV, 1 (4.8%) remained positive. Positive PB by BED group were <150 Gy, 22/121 (18.2%), >150‐200 Gy, 15/244 (6.1%) and >200 Gy, 6/193 (3.1%, p<0.001). Regression analyses revealed in LR BED (p=0.019), in IR HT (p=0.011) and BED (p=0.040), and in HR BED (p=0.004) as predictors of a positive PB. Biochemical freedom from failure (bFFF) at 7 years was 82.7%. bFFF by biopsy results were 84.7% for negative vs 59.2% for positive PB (p<0.001). Cox regression revealed GS (p=0.003), PSA (p< 0.001), BED (p=0.017) and PB (p=0.017) as significant predictors of bFFF. In LR BED (p=0.038) and PB (p=0.002), in IR BED (p=0.003), and in HR GS (p=0.006), PSA (p<0.001) and PB (p=0.038) remained significant. There were 53 deaths (9.1%) of which 8 were due to prostate cancer. Cause‐specific survival (CSS) at 7 years was 99.2% for negative vs 87.6% for positive PB (p<0.001).
|
|
